Date: November 03, 2026

Ref:- GHL/2026-27/EXCH/70

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('*Listing Regulations*')

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited ('**GHL/Company'**) at its meeting held today i.e. *Tuesday, November 03, 2026,* has *inter alia,* approved the following:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter & Half Year ended September 30, 2026 ('Financial Results'). The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Exhibit-I**.

   Further, we hereby declare and confirm that the Statutory Auditors of the Company, have issued the Limited Review Reports with an unmodified opinion on the Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2026 pursuant to the Listing Regulations.

2. The Project Budget of Rs. 997 Crores (including the cost of land) for construction of a 500 bedded hospital on the land parcel admeasuring 10560.36 sq. meters allotted by UP Housing & Development Board (UPAVP), at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh. The details as required under Regulation 30 are enclosed as **Annexure-A** (in continuation of our earlier intimation in this regard dated September 28, 2026).

The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.

The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 03:45 P.M.

Thanking You,

For Global Health Limited

RAHUL RANJAN
Digitally signed by RAHUL RANJAN
Date: 2026.11.03 15:59:59 +05'30'

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') which includes GHL Employee Welfare Trust ('the Trust') for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

   Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013





Tarun Gupta
Partner
Membership No. 507892

UDIN: 26507892KTIZMA2964

Place: Gurugram
Date: 03 November 2026

Global Health Limited
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India
CIN:L85110DL2004PLC128319
Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org
Statement of standalone unaudited financial results for the quarter and six months ended 30 September 2026

(₹ in millions, unless otherwise stated)

S No.	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
I	Revenue from operations	12,080.94	10,787.23	9,264.28	22,868.17	18,085.84	37,093.78
II	Other income	258.89	240.60	228.00	499.49	459.39	1,064.08
	Total income	**12,339.83**	**11,027.83**	**9,492.28**	**23,367.66**	**18,545.23**	**38,157.86**
III	**Expenses**						
	Cost of materials consumed	2,446.15	2,261.59	2,032.16	4,707.74	3,953.79	7,858.56
	Purchases of stock-in-trade	0.08	-	(0.44)	0.08	25.15	19.43
	Changes in inventories of stock-in-trade	-	-	0.52	-	40.13	46.11
	Employee benefits expense	3,013.97	2,854.73	2,483.33	5,868.70	4,812.78	9,892.59
	Finance costs	170.65	158.90	88.83	329.55	145.41	410.85
	Depreciation and amortisation expense	561.51	546.04	374.28	1,107.55	708.36	1,709.07
	Retainers and consultants fee	1,750.81	1,659.19	1,282.33	3,410.00	2,375.14	5,445.32
	Other expenses	1,965.90	1,716.28	1,540.65	3,682.18	3,007.31	6,283.16
	Total expenses	**9,909.07**	**9,196.73**	**7,801.66**	**19,105.80**	**15,068.07**	**31,665.09**
IV	**Profit before exceptional items and tax**	**2,430.76**	**1,831.10**	**1,690.62**	**4,261.86**	**3,477.16**	**6,492.77**
	Exceptional items (refer note 6)	-	-	(159.85)	-	(355.77)	(3.77)
V	**Profit before tax**	**2,430.76**	**1,831.10**	**1,850.47**	**4,261.86**	**3,832.93**	**6,496.54**
VI	Tax expenses						
	Current tax	610.43	545.75	358.62	1,156.18	771.89	1,345.72
	Tax pertaining to earlier years	-	-	-	-	-	(33.30)
	Deferred tax charge/(credit)	7.74	(87.72)	89.86	(79.98)	139.41	222.11
VII	**Profit after tax**	**1,812.59**	**1,373.07**	**1,401.99**	**3,185.66**	**2,921.63**	**4,962.01**
VIII	**Other comprehensive income**						
	(i) Items that will not be reclassified to statement of profit or loss	35.12	(63.50)	(10.67)	(28.38)	(7.66)	46.64
	(ii) Equity instruments through OCI	-	-	-	-	-	(1.60)
	(iii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(8.84)	15.98	2.69	7.14	1.93	(11.74)
	Total other comprehensive income	**26.28**	**(47.52)**	**(7.98)**	**(21.24)**	**(5.73)**	**33.30**
IX	**Total comprehensive income**	**1,838.87**	**1,325.55**	**1,394.01**	**3,164.42**	**2,915.90**	**4,995.31**
X	Paid-up equity share capital (face value of ₹ 2 each)	537.35	537.54	537.58	537.35	537.58	537.38
XI	Reserves (other equity)						39,588.28
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters and six months)						
	Basic (₹ per share)	6.75	5.11	5.22	11.85	10.87	18.46
	Diluted (₹ per share)	6.73	5.10	5.22	11.83	10.85	18.42

See accompanying notes to the standalone unaudited financial results

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Global Health Limited

Global Health Limited
CIN: L85110DL2004PLC128319
Note 1: Standalone balance sheet as at 30 September 2026

(₹ in millions, unless otherwise stated)

Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
ASSETS		
Property, plant and equipment	24,127.92	23,404.48
Right-of-use assets	6,306.49	5,489.10
Capital work-in-progress	1,987.93	1,197.01
Goodwill	52.16	-
Other intangible assets	126.15	137.85
Intangible assets under development	-	0.59
Financial assets		
Investments	3,893.68	3,893.68
Loans	1,309.42	1,436.30
Other financial assets	912.15	1,047.92
Deferred tax assets (net)	130.17	43.06
Income-tax assets (net)	356.40	356.40
Other non-current assets	1,425.47	804.88
Total non-current assets	**40,627.94**	**37,811.27**
Current assets		
Inventories	546.71	508.97
Financial assets		
Trade receivables	4,881.06	3,868.53
Cash and cash equivalents	2,045.27	959.08
Bank balances other than cash and cash equivalents	10,982.28	9,804.50
Loans	133.33	103.55
Other financial assets	378.78	286.48
Other current assets	265.23	172.31
Total current assets	**19,232.66**	**15,703.42**
Total assets	**59,860.60**	**53,514.69**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	537.35	537.38
Other equity	42,597.29	39,588.28
Total equity	**43,134.64**	**40,125.66**
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	5,175.68	4,492.02
Lease liabilities	2,892.44	2,048.62
Provisions	1,340.06	1,085.45
Other non-current liabilities	457.26	451.80
Total non-current liabilities	**9,865.44**	**8,077.89**
Current liabilities		
Financial liabilities		
Borrowings	254.92	87.05
Lease liabilities	283.60	198.90
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	1,089.93	729.49
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,538.28	1,291.41
Other financial liabilities	1,459.39	1,198.52
Other current liabilities	1,590.53	1,515.04
Provisions	312.58	290.73
Current tax liabilities (net)	331.29	-
Total current liabilities	**6,860.52**	**5,311.14**
Total equity and liabilities	**59,860.60**	**53,514.69**

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Global Health Limited

Global Health Limited
CIN: L85110DL2004PLC128319
Note 2: Standalone Statement of Cash Flow for the period ended 30 September 2026

(₹ in millions, unless otherwise stated)

Particulars	For the period ended 30 September 2026 (Unaudited)	For the period ended 30 September 2025 (Unaudited)
A CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	4,261.86	3,832.93
Adjustments for:		
Depreciation and amortisation expense	1,107.55	708.36
Finance costs	329.55	145.41
Employee share based payment expense	120.10	171.44
Interest income	(465.48)	(436.69)
Grant income	(138.01)	(311.89)
Loss allowance and bad debts written off	52.43	40.89
Advances written off (net)	0.06	-
Unrealised foreign exchange (gain)/loss (net)	(0.50)	6.85
Gain on sale of property, plant and equipments (net)	(0.87)	(0.33)
Exceptional items	-	(355.77)
Reversal for contingencies	-	(7.04)
Operating profit before working capital changes	**5,266.69**	**3,794.16**
Movement in working capital:		
Trade receivables	(1,065.13)	(754.10)
Inventories	(37.73)	5.25
Other assets	(312.02)	(165.13)
Trade payables	605.29	446.76
Other liabilities	379.21	142.60
Provisions	248.08	(90.76)
Cash flows from operating activities	**5,084.39**	**3,378.78**
Income-tax paid (net)	(824.88)	(764.40)
Net cash flows generated from operating activities (A)	**4,259.51**	**2,614.38**
B CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property plant and equipments, capital work-in-progress and intangible assets (including capital advances, capital creditors and deferred payment liabilities)	(2,973.54)	(3,592.55)
Movement in other bank balances and deposits (net)	(965.79)	4,142.11
Interest received	409.39	438.27
Loans repayment from subsidiaries	97.09	79.55
Proceeds from disposal of property, plant and equipments	3.95	1.76
Payment for acquisition of leasehold land	-	(128.71)
Investment in subsidiary companies	-	(15.10)
Net cash flows (used in)/generated from investing activities (B)	**(3,428.90)**	**925.33**
C CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from non-current borrowings	914.71	2,006.93
Repayment of non-current borrowings	(62.50)	-
Interest paid on borrowings	(176.47)	(95.32)
Proceeds from issue of equity share capital (net of share issue expenses)	0.17	0.41
Purchase of treasury shares	(142.35)	-
Dividend paid	(99.23)	-
Payment of interest on lease payments	(145.85)	(104.41)
Principal elements of lease liabilities	(32.90)	(32.03)
Premium for employee stock purchase shares to employees of subsidiary companies	-	18.13
Net cash generated from financing activities (C)	**255.58**	**1,793.71**
Net increase in cash and cash equivalents (A+B+C)	1,086.19	5,333.42
Cash and cash equivalents at the beginning of the year	959.08	1,900.65
Cash and cash equivalents at the end of the period	**2,045.27**	**7,234.07**
Reconciliation of cash and cash equivalents as per statement of cash flow		
Balances with banks in current accounts	423.23	408.96
Cheques on hand	0.01	0.14
Cash on hand	27.03	21.36
Bank deposits with original maturity less than three months	1,595.00	6,803.61
	2,045.27	**7,234.07**

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Global Health Limited

Global Health Limited
Notes to the standalone unaudited financial results:

3 The above standalone unaudited financial results of Global Health Limited ('the Company') , for the quarter and six months ended 30 September 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 03 November 2026 and a limited review of the same has been carried out by the statutory auditors.

4 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).

5 The Chief Operating Decision Maker (CODM) examines the Company's performance from a service perspective and has identified the healthcare services as single business segment.

6 **Exceptional items include:** **(₹ in millions)**

Particulars	Quarter ended	Six months ended	Year ended
	30 September 2025	30 September 2025	31 March 2026
Export Promotion Capital Goods (EPCG) Obligation *(Refer point a below)*	-	(195.92)	(195.92)
Stamp duty on merger *(Refer point b below)*	(159.85)	(159.85)	(159.85)
Impact of new labour codes *(Refer point c below)*	-	-	352.00
Total	**(159.85)**	**(355.77)**	**(3.77)**

a During the six months ended 30 September 2025, the Company reversed interest liability on Export Promotion Capital Goods (EPCG) amounting to ₹ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Company. The Company had achieved the required export obligation within the prescribed timeline.

b Stamp duty was payable in connection with the merger of Medanta Holdings Private Limited with the Company, however during the quarter ended 30 September 2025, the Company reversed stamp duty amounting to ₹ 159.85 millions payable to Government of National Capital Territory of Delhi, pursuant to adjudication of its stamp duty application.

c On 21 November 2025, the Government of India notified the four Labour Codes—namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating 29 existing labour laws.
The Company had evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Company had presented such incremental impact, aggregating to ₹352.00 millions under 'Exceptional items'.

The Company continues to monitor the finalisation of the State Rules and any further government clarifications on other aspects of the Labour Codes.

7a. The Company executed a Business Transfer Agreement (BTA) with Asian Institute of Oncology Private Limited for a 79 bedded Advanced Super Speciality Hospital primarily engaged in providing oncology services in Indore in April 2026.

b. During the quarter ended 30 September 2026, the Company has been allotted under online auction from UP Housing & Development Board (UPAVP) a land parcel situated at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh measuring 10560.36 sq. meters on free hold basis. Subsequent to the quarter ended 30 September 2026, the Board of Directors approved the proposed development of a 500-bedded hospital on the aforesaid land parcel.

8 **Employee benefits expense include:** **(₹ in millions)**

Particulars	Quarter ended			Six months ended		Year ended
	30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
Employee share based payment expense	59.83	60.27	95.72	120.10	171.44	368.57

9 The standalone financial results also include the financial results of GHL Employee Welfare Trust.

For and on behalf of the Board of Directors of Global Health Limited

Dr. Naresh Trehan
Chairman and Managing Director

Place : Gurugram
Date : 03 November 2026

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Global Health Limited

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Tarun Gupta
Partner
Membership No. 507892

UDIN: 26507892DKCSRC2758

Place: Gurugram
Date: 03 November 2026

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure 1

List of entities included in the Statement

S. No.	Name	Relationship with the Holding Company
1	Global Health Patliputra Private Limited	Wholly owned subsidiary
2	GHL Pharma & Diagnostic Private Limited	Wholly owned subsidiary
3	GHL Hospital Limited	Subsidiary
4	Global Health Institute of Medical Sciences Foundation	Wholly owned subsidiary
5	Medanta Foundation- Poor and Needy Patients Welfare Trust	Trust



Global Health Limited
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India
CIN:L85110DL2004PLC128319
Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org
Statement of consolidated unaudited financial results for the quarter and six months ended 30 September 2026

S. No.	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
I	Revenue from operations	14,690.43	13,040.51	10,992.80	27,730.94	21,301.24	44,102.66
II	Other income	236.15	221.64	196.68	457.79	401.18	985.94
	Total income	**14,926.58**	**13,262.15**	**11,189.48**	**28,188.73**	**21,702.42**	**45,088.60**
III	**Expenses**						
	Cost of materials consumed	2,786.78	2,571.88	2,266.92	5,358.66	4,397.69	8,821.31
	Purchases of stock-in-trade	458.15	407.32	287.84	865.47	605.74	1,173.00
	Changes in inventories of stock-in-trade	(32.36)	(35.49)	0.80	(67.85)	(57.30)	(26.30)
	Employee benefits expense	3,346.06	3,192.73	2,743.34	6,538.79	5,307.38	10,961.08
	Finance costs	280.85	266.76	171.12	547.61	308.97	791.14
	Depreciation and amortisation expense	707.97	689.77	497.26	1,397.74	948.34	2,225.40
	Retainers and consultants fee	2,130.11	2,007.26	1,549.45	4,137.37	2,916.45	6,579.68
	Other expenses	2,300.75	2,029.29	1,834.46	4,330.04	3,551.37	7,402.91
	Total expenses	**11,978.31**	**11,129.52**	**9,351.19**	**23,107.83**	**17,978.64**	**37,928.22**
IV	**Profit before exceptional items and tax**	**2,948.27**	**2,132.63**	**1,838.29**	**5,080.90**	**3,723.78**	**7,160.38**
	Exceptional items (refer note 6)	-	-	(159.85)	-	(355.77)	10.21
V	**Profit before tax**	**2,948.27**	**2,132.63**	**1,998.14**	**5,080.90**	**4,079.55**	**7,150.17**
VI	**Tax expenses**						
	Current tax	642.90	545.75	358.62	1,188.65	771.89	1,345.72
	Tax pertaining to earlier years	-	-	-	-	-	(33.30)
	Deferred tax charge	113.93	14.36	55.52	128.29	133.84	297.07
VII	**Profit after tax**	**2,191.44**	**1,572.52**	**1,584.00**	**3,763.96**	**3,173.82**	**5,540.68**
VIII	**Other comprehensive income**						
	(i) Items that will not be reclassified to statement of profit or loss	34.74	(68.99)	(12.34)	(34.25)	(9.23)	50.86
	(ii) Equity instruments through OCI	-	-	-	-	-	(1.60)
	(iii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(8.74)	17.36	3.11	8.62	2.33	(12.81)
	Total other comprehensive income	**26.00**	**(51.63)**	**(9.23)**	**(25.63)**	**(6.90)**	**36.45**
IX	**Total comprehensive income**	**2,217.44**	**1,520.89**	**1,574.77**	**3,738.33**	**3,166.92**	**5,577.13**
	Profit after tax attributable to:						
	(i) Owners of the Holding Company	2,206.72	1,587.27	1,584.41	3,793.99	3,174.50	5,564.60
	(ii) Non-controlling interests	(15.28)	(14.75)	(0.41)	(30.03)	(0.68)	(23.92)
	Other comprehensive income attributable to:						
	(i) Owners of the Holding Company	25.99	(51.62)	(9.23)	(25.63)	(6.90)	36.44
	(ii) Non-controlling interests	0.01	(0.01)	-	-	-	0.01
	Total comprehensive income attributable to:						
	(i) Owners of the Holding Company	2,232.71	1,535.65	1,575.18	3,768.36	3,167.60	5,601.04
	(ii) Non-controlling interests	(15.27)	(14.76)	(0.41)	(30.03)	(0.68)	(23.91)
X	Paid-up equity share capital (face value of ₹ 2 each)	537.35	537.54	537.58	537.35	537.58	537.38
XI	Reserves (other equity)						39,078.32
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters and six months)						
	Basic (₹ per share)	8.21	5.91	5.89	14.12	11.81	20.71
	Diluted (₹ per share)	8.20	5.90	5.89	14.09	11.79	20.66

See accompanying notes to the consolidated unaudited financial results

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

Global Health Limited ★

Global Health Limited
CIN:L85110DL2004PLC128319
Note 1: Consolidated balance sheet as at 30 September 2026

(₹ in millions, unless otherwise stated)

Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
ASSETS		
Non-current assets		
Property, plant and equipment	30,391.47	29,623.44
Right-of-use assets	8,983.37	8,163.70
Capital work-in-progress	2,065.89	1,322.05
Goodwill	52.16	-
Other intangible assets	144.73	160.46
Intangible assets under development	0.98	1.57
Financial assets		
Investments	25.50	25.50
Other financial assets	992.70	1,116.88
Deferred tax assets (net)	186.99	156.46
Income-tax assets (net)	516.54	554.78
Other non-current assets	1,815.39	1,176.00
Total non-current assets	**45,175.72**	**42,300.84**
Current assets		
Inventories	883.22	789.83
Financial assets		
Trade receivables	5,223.24	4,111.85
Cash and cash equivalents	2,962.41	1,273.33
Bank balances other than cash and cash equivalents	11,046.06	10,028.95
Other financial assets	432.11	321.59
Other current assets	338.91	223.65
Total current assets	**20,885.95**	**16,749.20**
Total assets	**66,061.67**	**59,050.04**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	537.35	537.38
Other equity	42,696.56	39,078.32
Non-controlling interests	197.02	227.05
Total equity	**43,430.93**	**39,842.75**
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	6,588.46	6,011.16
Lease liabilities	6,247.92	5,259.41
Other financial liabilities	3.06	3.39
Provisions	1,420.27	1,139.21
Deferred tax liabilities (net)	150.19	-
Other non-current liabilities	540.51	522.81
Total non-current liabilities	**14,950.41**	**12,935.98**
Current liabilities		
Financial liabilities		
Borrowings	360.69	299.59
Lease liabilities	330.27	330.30
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	1,290.31	879.25
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,811.71	1,544.45
Other financial liabilities	1,555.56	1,332.28
Other current liabilities	1,677.68	1,585.57
Provisions	322.82	299.87
Current tax liabilities (net)	331.29	-
Total current liabilities	**7,680.33**	**6,271.31**
Total equity and liabilities	**66,061.67**	**59,050.04**

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

Global Health Limited ★

Global Health Limited
CIN:L85110DL2004PLC128319
Note 2: Consolidated statement of cash flow for the period ended 30 September 2026

(₹ in millions, unless otherwise stated)

Particulars	For the period ended 30 September 2026 Unaudited	For the period ended 30 September 2025 Unaudited
A CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	5,080.90	4,079.55
Adjustments for:		
Depreciation and amortisation expense	1,397.74	948.34
Finance costs	547.61	308.97
Employee share based payment expense	126.49	178.81
Grant income	(142.23)	(312.48)
Interest income	(425.20)	(377.93)
Loss allowance and bad debts written off	41.61	40.14
(Reversal)/provision for contingencies	-	(7.04)
Loss/(gain) on de-recognition of lease liabilities and right of use assets	1.24	(1.81)
Exceptional items	-	(355.77)
Gain on sale of property, plant and equipments (net)	(0.98)	(0.33)
Liabilities written back	(0.04)	-
Unrealised foreign exchange (gain)/loss (net)	(7.43)	16.08
Operating profit before working capital changes	**6,619.71**	**4,516.53**
Movement in working capital:		
Trade receivables	(1,153.17)	(771.29)
Other assets	(242.64)	(205.03)
Inventories	(93.39)	(61.17)
Trade payables	678.36	555.77
Other liabilities	413.10	153.60
Provisions	269.76	(86.25)
Cash flows from operating activities	**6,491.73**	**4,102.16**
Income-tax paid (net)	(813.61)	(816.87)
Net cash flows generated from operating activities (A)	**5,678.12**	**3,285.29**
B CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipments, capital work-in-progress and intangible assets (including capital advances, capital creditors and deferred payment liabilities)	(3,391.38)	(4,127.11)
Payment for acquisition of land	-	(128.71)
Proceeds from disposal of property, plant and equipments	6.27	2.51
Movement in other bank balances and deposits (net)	(804.74)	4,338.88
Interest received	360.45	379.05
Net cash flows (used in)/generated from investing activities (B)	**(3,829.40)**	**464.62**
C CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from non-current borrowings	913.85	2,006.79
Repayment of non-current borrowings	(274.77)	(49.55)
Interest paid on borrowings	(231.96)	(173.78)
Proceeds from issue of equity share capital to non-controlling interest	-	15.00
Proceeds from issue of equity share capital (net of share issue expenses)	0.17	0.41
Purchase of treasury shares	(142.35)	-
Dividend paid	(99.23)	-
Payment of interest on lease payments	(240.71)	(194.72)
Principal elements of lease liabilities	(84.64)	(64.22)
Net cash flows (used in)/generated from financing activities (C)	**(159.64)**	**1,539.93**
Net increase in cash and cash equivalents (A+B+C)	1,689.08	5,289.84
Cash and cash equivalents at the beginning of the year	1,273.33	2,302.00
Cash and cash equivalents at the end of the period	**2,962.41**	**7,591.84**
Reconciliation of cash and cash equivalents as per statement of cash flow		
Balances with banks in current accounts	518.64	463.37
Cheques on hand	0.01	0.14
Cash on hand	36.59	30.40
Bank deposits with original maturity less than three months	2,407.17	7,097.93
	2,962.41	**7,591.84**

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Global Health Limited

Global Health Limited
Notes to the consolidated unaudited financial results:

3 The above consolidated unaudited financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group'), for the quarter and six months ended 30 September 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 03 November 2026 and a limited review of the same has been carried out by the statutory auditors.

4 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).

5 The Chief Operating Decision Maker (CODM) examines the Group's performance from a service perspective and has identified the healthcare services as single business segment.

6 **Exceptional items include:** **(₹ in millions)**

Particulars	Quarter ended	Six months ended	Year ended
	30 September 2025	30 September 2025	31 March 2026
Export Promotion Capital Goods (EPCG) Obligation *(Refer point a below)*	-	(195.92)	(195.92)
Stamp duty on merger *(Refer point b below)*	(159.85)	(159.85)	(159.85)
Impact of new Labour Codes *(Refer point c below)*	-	-	365.98
Total	**(159.85)**	**(355.77)**	**10.21**

a During the six months ended 30 September 2025, the Holding Company reversed interest liability on Export Promotion Capital Goods (EPCG) amounting to ₹ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Holding Company. The Holding Company had achieved the required export obligation within the prescribed timeline.

b Stamp duty was payable in connection with the merger of Medanta Holdings Private Limited with the Holding Company, however during the quarter ended 30 September 2025, the Holding Company reversed stamp duty amounting to ₹ 159.85 millions payable to Government of National Capital Territory of Delhi, pursuant to adjudication of its stamp duty application.

c On 21 November 2025, the Government of India notified the four Labour Codes—namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued Central Rules and related FAQs.

The Group had evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Group had presented such incremental impact, aggregating to ₹365.98 millions under 'Exceptional items'.

The Group continues to monitor the finalisation of the State Rules and any further government clarifications on other aspects of the Labour Codes.

7a The Holding Company executed a Business Transfer Agreement (BTA) with Asian Institute of Oncology Private Limited for a 79 bedded Advanced Super Speciality Hospital primarily engaged in providing oncology services in Indore in April 2026.

b During the quarter ended 30 September 2026, the Holding Company has been allotted under online auction from UP Housing & Development Board (UPAVP) a land parcel situated at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh measuring 10560.36 sq. meters on free hold basis. Subsequent to the quarter ended 30 September 2026, the Board of Directors approved the proposed development of a 500-bedded hospital on the aforesaid land parcel.

8 **Employee benefits expense include:** **(₹ in millions)**

Particulars	Quarter ended			Six months ended		Year ended
	30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
Employee share based payment expense	62.88	63.61	100.04	126.49	178.81	382.98

9 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Dr. Naresh Trehan
Chairman and Managing Director

Place : Gurugram
Date : 03 November 2026

Global Health Limited

Annexure A

Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with relevant SEBI Circular(s)

S. No.	Particulars	Information Required
1.	Existing capacity	As on September 30, 2026, Medanta has existing capacity of 3,811 beds.
2.	Existing capacity utilization	Currently, Medanta Hospitals are operating in Gurugram, Indore, Ranchi, Lucknow, Patna and Noida.
3.	Proposed capacity addition	The Land Parcel allows construction of 500 bedded multi-specialty Hospital (as against initial assessment of 350 beds with proposal to acquire additional FSI).
4.	Period within which the proposed capacity is to be added	The proposed capacity will be added over the next 3-4 years in a phased manner.
5.	Investment required	Land purchase cost is Rs. 165.82 crores. The estimated project cost including land is of Rs. 997 crores.
6.	Mode of financing	Purchase of Land Parcel is proposed to be funded through Internal accruals while funding for the entire project will be through a mix of internal accruals and debt.
7.	Rationale	Ghaziabad presents a compelling healthcare investment opportunity, underpinned by a large and expanding population, accelerating urbanisation, sustained residential and commercial development, and strong connectivity with the Delhi-NCR region. The city also functions as a significant referral catchment for east Delhi, Meerut, Saharanpur, Hapur, Bulandshahr and the broader western Uttar Pradesh belt. The proposed site at Siddharth Vihar offers a strategically positioned location for a large-scale integrated healthcare facility in one of the city's fastest-developing micro-markets. The project would enable the Company to address growing demand for advanced medical care while leveraging its established clinical expertise, brand equity, technology capabilities, medical talent and existing healthcare ecosystem.